Willem M. Lijfering
|
2009
|
Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship
between venous and arterial thrombosis: a review of the literature from a causal perspective.
Semin Thromb Hemost. 2011;37(8):885–896.
|
Salley Pels
|
2009
|
Pels SG. Current therapies in primary immune thrombocytopenia. Semin Thromb Hemost.
2011;37(6):621–630.
|
Adam Cuker
|
2010
|
Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. Semin
Thromb Hemost. 2012;38(1):31–37.
|
Giridhara Rao Jayandharan
|
2010
|
Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia:
from diagnosis to therapy. Semin Thromb Hemost. 2012;38(1):64–78.
|
Timea Szanto
|
2010
|
Szántó T, Joutsi-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand
disease and platelet function. Semin Thromb Hemost. 2012;38(1):55–63.
|
Birgitta Salmela
|
2010
|
Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of
patients using new oral anticoagulants: bleeding risk, compliance, and coagulation
analysis. Semin Thromb Hemost. 2012;38(1):23–30.
|
Pia Riittaa-Maria Siljander
|
2010
|
Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitalented
participants in intercellular communication. Semin Thromb Hemost. 2012;38(1):102–113.
|
Romaric Lacroix
|
2011
|
Lacroix R, Dignat-George F. Microparticles: new protagonists in pericellular and intravascular
proteolysis. Semin Thromb Hemost. 2013;39(1):33–39.
|
Brad McEwen
|
2011
|
McEwen BJ, Morel-Kopp MC, Chen W, Tofler GH, Ward CM. Effects of omega-3 polyunsaturated
fatty acids on platelet function in healthy subjects and subjects with cardiovascular
disease. Semin Thromb Hemost. 2013;39(1):25–32.
|
Neil A. Goldenberg
|
2011
|
Bernard TJ, Armstrong-Wells J, Goldenberg NA. The institution-based prospective inception
cohort study: design, implementation, and quality assurance in pediatric thrombosis
and stroke research. Semin Thromb Hemost. 2013;39(1):10–14.
|
Vivien Chen
|
2011
|
Chen VM. Tissue factor de-encryption, thrombus formation, and thiol-disulfide exchange.
Semin Thromb Hemost. 2013;39(1):40–47.
|
Joseph E. Italiano, Jr.
|
2011
|
Italiano JE Jr. Unraveling mechanisms that control platelet production. Semin Thromb
Hemost. 2013;39(1):15–24.
|
Vivian Xiaoyan Du
|
2012/2013
|
Du VX, Huskens D, Maas C, Al Dieri R, de Groot PG, de Laat B. New insights into the
role of erythrocytes in thrombus formation. Semin Thromb Hemost. 2014;40(1):72–80.
|
Andrew Yee
|
2012/2013
|
Yee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Hemost. 2014;40(1):17–27.
|
Sarah O'Brien
|
2012/2013
|
O'Brien SH. Contraception-related venous thromboembolism in adolescents. Semin Thromb
Hemost. 2014;40(1):66–71.
|
Veronica Flood
|
2012/2013
|
Flood VH. Perils, problems, and progress in laboratory diagnosis of von Willebrand
disease. Semin Thromb Hemost. 2014;40(1):41–48.
|
Julie Tange
|
2012/2013
|
Tange JI, Grill D, Koch CD, Ybabez RJ, Krekelberg BJ, Fylling KA, Wiese CR, Baumann
NA, Block DR, Karon BS, Chen D, Pruthi RK. Local verification and assignment of mean
normal prothrombin time and international sensitivity index values across various
instruments: recent experience and outcome from North America. Semin Thromb Hemost.
2014;40(1):115–120.
|
Kent Chapman
|
2012/2013
|
Chapman K, Yuen S. Therapy for thrombotic thrombocytopenia purpura: past, present,
and future. Semin Thromb Hemost. 2014;40(1):34–40.
|
Andreas Tiede
|
2014
|
Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia A: limitations,
consequences, and challenges. Semin Thromb Hemost. 2014;40(7):803–811.
|
Wendy Lim
|
2014
|
Lim W. Thrombotic risk in the antiphospholipid syndrome. Semin Thromb Hemost. 2014;40(7):741–746.
|
Susana Nobre Fernandes
|
2014
|
Fernandes S, Carvalho M, Lopes M, Araújo F. Impact of an individualized prophylaxis
approach on young adults with severe hemophilia. Semin Thromb Hemost. 2014;40(7):785–789.
|
Maria Elisa Mancuso
|
2014
|
Mancuso ME, Fasulo MR. Thrombin generation assay as a laboratory monitoring tool during
by-passing therapy in patients with hemophilia and inhibitors. Semin Thromb Hemost.
2016;42(1):30–35.
|
Coen Maas
|
2014
|
Tersteeg C, Fijnheer R, Deforche L, Pasterkamp G, de Groot PG, Vanhoorelbeke K, de
Maat S, Maas C. Keeping von Willebrand factor under control: alternatives for ADAMTS13.
Semin Thromb Hemost. 2016;42(1):9–17.
|
Riten Kumar
|
2014
|
Kumar R, Dunn A, Carcao M. Changing paradigm of hemophilia management: extended half-life
factor concentrates and gene therapy. Semin Thromb Hemost. 2016;42(1):18–29.
|
Juraj Sokol
|
2015
|
Sokol J, Skerenova M, Jedinakova Z, Simurda T, Skornova I, Stasko J, Kubisz P. Progress
in the understanding of sticky platelet syndrome. Semin Thromb Hemost 2017;43(1):8–13
|
Ljubica Jovanović
|
2015
|
Jovanovic L, Antonijevic N, Novakovic T, Savic N, Terzic B, Zivkovic I, Radovanovic
N, Asanin M. Practical aspects of monitoring of antiplatelet therapy. Semin Thromb
Hemost 2017;43(1):14–23
|
Lucia Stanciakova
|
2015
|
Stanciakova L, Dobrotova M, Jedinakova Z, Duraj L, Skornova I, Korinkova L, Holly
P, Danko J, Stasko J, Kubisz P. Monitoring of hemostasis and management of anticoagulant
thromboprophylaxis in pregnant women with increased risk of fetal loss. Semin Thromb
Hemost. 2016;42(6):612–621.
|
Tina Biss
|
2015
|
Biss TT. Venous thromboembolism in children: is it preventable? Semin Thromb Hemost.
2016;42(6):603–611.
|
Tobias Fuchs
|
2015
|
Jiménez-Alcázar M, Kim N, Fuchs TA. Circulating extracellular DNA: cause or consequence
of thrombosis? Semin Thromb Hemost. 2017;43(6):553–561
|
Jonathan M. Coutinho
|
2015
|
Silvis SM, Middeldorp S, Zuurbier SM, Cannegieter SC, Coutinho JM. Risk factors for
cerebral venous thrombosis. Semin Thromb Hemost. 2016;42(6):622–631.
|
Soundarya Selvam
|
2016
|
Selvam S, James P. Angiodysplasia in von Willebrand disease: understanding the clinical
and basic science. Semin Thromb Hemost. 2017 Sep;43(6):572–580.
|
Vincent Muczynski
|
2016
|
Muczynski V, Christophe OD, Denis CV, Lenting PJ. Emerging therapeutic strategies
in the treatment of hemophilia A. Semin Thromb Hemost. 2017;43(6):581–590.
|
Karen Schreiber
|
2016
|
Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S, Regan L, Roccatello
D, Robinson SE, Sciascia S, Seed PT, Watkins L, Hunt BJ. HYdroxychloroquine to Improve
Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) protocol: a
multinational randomized controlled trial of hydroxychloroquine versus placebo in
addition to standard treatment in pregnant women with antiphospholipid syndrome or
antibodies. Semin Thromb Hemost. 2017;43(6):562–571.
|
Jasmine Wee Ting Tay
|
2016
|
Tay J, Tiao J, Hughes Q, Jorritsma J, Gilmore G, Baker R. Circulating microRNA as
thrombosis sentinels: caveats and considerations. Semin Thromb Hemost. 2018;44(3):206–215.
|
Adi J. Klil-Drori
|
2016
|
Klil-Drori AJ, Tagalakis V. Direct oral anticoagulants in end-stage renal disease.
Semin Thromb Hemost. 2018;44(4):353–363.
|
Ivar van Asten
|
2017
|
van Asten I, Schutgens REG, Urbanus RT. Toward flow cytometry based platelet function
diagnostics. Semin Thromb Hemost. 2018;44(3):197–205.
|
Elodie Laridan
|
2017
|
Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and
venous thrombosis. Semin Thromb Hemost. 2019;45(1):86–93.
|
Leonardo Pasalic
|
2017
|
Blennerhassett R, Curnow J, Pasalic L. Immune-mediated thrombotic thrombocytopenic
purpura: a narrative review of diagnosis and treatment in adults. Semin Thromb Hemost.
2020;46(3):289–301
|
Yvonne Brennan
|
2017
|
Brennan Y, Favaloro EJ, Curnow J. To maintain or cease non-vitamin K antagonist oral
anticoagulants prior to minimal bleeding risk procedures: a review of evidence and
recommendations. Semin Thromb Hemost. 2019;45(2):171–179.
|
Mark Schreuder
|
2018
|
Schreuder M, Reitsma PH, Bos MHA. Reversal agents for the direct factor Xa inhibitors:
biochemical mechanisms of current and newly emerging therapies. Semin Thromb Hemost.
2020;46(8):986–998.
|
James McFadyen
|
2018
|
Stevens H, McFadyen JD. Platelets as central actors in thrombosis-reprising an old
role and defining a new character. Semin Thromb Hemost. 2019;45(8):802–809.
|
David Rabbolini
|
2018
|
Mason GA, Rabbolini DJ. The current role of platelet function testing in clinical
practice. Semin Thromb Hemost. 2021;47(7):843–854.
|
Janka Zolkova
|
2018
|
Zolkova J, Sokol J, Simurda T, Vadelova L, Snahnicanova Z, Loderer D, Dobrotova M,
Ivankova J, Skornova I, Lasabova Z, Kubisz P, Stasko J. Genetic background of von
Willebrand disease: history, current state and future perspectives. Semin Thromb Hemost.
2020;46(4):484–500.
|
Tomáš Bolek
|
2018
|
Bolek T, Samoš M, Škorňová I, Galajda P, Staško J, Kubisz P, Mokáň M. Proton pump
inhibitors and dabigatran therapy: impact on gastric bleeding and dabigatran plasma
levels. Semin Thromb Hemost. 2019;45(8):846–850.
|
Fraser Macrae
|
2018
|
Kearney KJ, Ariëns RAS, Macrae FL. The role of fibrin(ogen) in wound healing and infection
control. Semin Thromb Hemost. 2022;48(2):174–187.
|
Elisa Danese
|
2019
|
Danese E, Montagnana M, Gelati M, Lippi G. The role of epigenetics in the regulation
of hemostatic balance. Semin Thromb Hemost. 2021;47(1):53–62.
|
Soracha Ward
|
2019
|
Ward S, O'Sullivan JM, O'Donnell JS. The biological significance of von Willebrand
factor O linked glycosylation. Semin Thromb Hemost. 2021;47(7):855–861.
|
Jonathan Douxfils
|
2019
|
Douxfils J, Morimont L, Bouvy C. Oral contraceptives and venous thromboembolism: focus
on testing that may enable prediction and assessment of the risk. Semin Thromb Hemost.
2020;46(8):872–886.
|
Erik Klok
|
2019
|
Boon GJAM, Huisman MV, Klok FA. Why, whom, and how to screen for chronic thromboembolic
pulmonary hypertension after acute pulmonary embolism. Semin Thromb Hemost. 2021;47(6):692–701.
|
Michelle Lavin
|
2019
|
Byrne B, Ryan K, Lavin M. Current challenges in the peripartum management of women
with von Willebrand disease. Semin Thromb Hemost. 2021;47(2):217–228.
|
Deeksha Khialani
|
2019
|
Khialani D, Rosendaal F, Vlieg AVH. Hormonal contraceptives and the risk of venous
thrombosis. Semin Thromb Hemost. 2020;46(8):865–871.
|
Hanny Al-Samkari
|
2020
|
Al-Samkari H. Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic
telangiectasia: a practical, evidence-based guide for clinicians. Semin Thromb Hemost.
2022;48(5):514–528.
|
Matthias M Engelen
|
2020
|
Engelen MM, Vandenbriele C, Balthazar T, Claeys E, Gunst J, Guler I, Jacquemin M,
Janssens S, Lorent N, Liesenborghs L, Peerlinck K, Pieters G, Rex S, Sinonquel P,
Van der Linden L, Van Laer C, Vos R, Wauters J, Wilmer A, Verhamme P, Vanassche T.
Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin
Thromb Hemost. 2021;47(4):362–371.
|
Ellen Driever
|
2020
|
Driever EG, Lisman T. Effects of inflammation on hemostasis in acutely ill patients
with liver disease. Semin Thromb Hemost. 2022;48(5):596–606.
|
Maria Selvadurai
|
2020
|
Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of thrombosis in heparin-induced thrombocytopenia
and vaccine-induced immune thrombotic thrombocytopenia. Semin Thromb Hemost. 2023;49(5):444–452.
|
Gudula Boon
|
2021
|
de Jong CMM, Boon GJAM, Le YNJ, Barco S, Siegerink B, Klok FA. The post-venous thromboembolism
functional status scale: from call to action to application in research, extension
to COVID-19 patients, and its use in clinical practice. Semin Thromb Hemost. 2023;49(7):764–773.
|
Hunter B. Moore
|
2021
|
Moore HB. Fibrinolysis shutdown and hypofibrinolysis are not synonymous terms: the
clinical significance of differentiating low fibrinolytic states. Semin Thromb Hemost.
2023;49(5):433–443.
|
Sol Schulman
|
2021
|
Park JK, Brake MA, Schulman S. Human genetic variation in F3 and its impact on tissue
factor-dependent disease. Semin Thromb Hemost. 2024;50(2):188–199.
|
Lauren G. Poole
|
2022
|
Capece GE, Luyendyk JP, Poole lG. Fibrinolysis-mediated pathways in acute liver injury.
Semin Thromb Hemost. 2024;50(4):638–647.
|
Aisling Rehill
|
2022
|
Noone D, Preston RJS, Rehill AM. The role of myeloid cells in thromboinflammatory
disease. Semin Thromb Hemost. 2024:10.1055/s-0044-1782660.
|
Harvey Roweth
|
2022
|
Roweth HG. Platelet contributions to the (pre)metastatic tumor microenvironment. Semin
Thromb Hemost. 2024;50(3):455–461.
|